Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 301 - 350 out of 6,220

Document Document Title
WO/2010/112946A9
The invention relates to adamantane bisurea derivatives and their use. Adamantane bisurea derivatives are obtained by reaction of adamantane diamine with appropriate isocyanate, or by in situ preparation of adamantane isocyanate from ada...  
WO/2010/127558A1
Substituted benzoyl urea compounds, preparation methods and pharmaceutical uses thereof are disclosed. The compounds are shown by general structure formula (I), wherein R1, R2 and R3 are defined as those in the description. The compounds...  
WO/2010/128062A1
The invention relates to the use of O-imino-iso-urea compounds as source of radicals to polymerizable compositions comprising these O-imino-iso-urea and to new O-imino-iso-urea compounds. The O-lmino-isoureas compounds are compounds of t...  
WO/2010/122968A1
Disclosed is a compound useful as an anti-obesity agent. Studies have been made on compounds which have a DGAT1 inhibitory activity and are therefore promising active ingredients for pharmaceutical compositions for treating obesity, type...  
WO/2010/086878A3
The present invention relates to novel compounds of general formula (I) which are thyroid receptor ligands and are preferably selective for the thyroid hormone receptor beta. Further, the present invention relates to processes of prepari...  
WO/2010/120138A2
The present invention relates to a salicylaldehyde chiral compound (chemical formula 1) and a naphtholaldehyde chiral compound (chemical formula 2), wherein a –OH group and a carbonyl group are adjacent to each other on a benzene ring....  
WO/2010/080795A3
Provided is a complex of hydrogen peroxide and at least one compound represented by Formula (I): wherein X is ( ), -C(R3)3, -C=C(R3), -O(R3), -N(R3)2, or -S(R3); and R1, R2, and R3 are each independently selected from H, alkyl, alkenyl, ...  
WO/2010/112946A1
The invention relates to adamantane bisurea derivatives and their use. Adamantane bisurea derivatives are obtained by reaction of adamantane diamine with appropriate isocyanate, or by in situ preparation of adamantane isocyanate from ada...  
WO/2010/113848A1
Disclosed is a compound represented by formula (I) or the like, which serves as an agent for treatment of diseases that are induced by production, secretion and/or deposition of amyloid β protein. Specifically disclosed is a compound re...  
WO2010110555A2
The present invention relates to a method for obtaining optically pure amino acids, including optical resolution and optical conversion. The method of the present invention significantly shortens the time taken for optical transformation...  
WO/2010/062490A3
The present invention provides methods of forming carbamates, ureas, and isocyanates. In certain embodiments these methods include the step of reacting an amine with an ester-substituted diaryl carbonate to form an activated carbamate wh...  
WO/2010/062158A3
The present invention relates to the synthesis of lipophilic or immobilized monobasic phosphate (H2PO4) ionophores (7, 8a, 8b and 11) to be used as ion recognition molecules for monobasic phosphate (H2PO4") in the cocktail preparation of...  
WO/2010/087318A1
Disclosed is a curable composition for a transfer material, which exhibits very good transferability in a nanoimprint process, while having a high selectivity between the dry etching rates by an argon gas and an oxygen gas. The curable c...  
WO/2010/081683A1
The present invention provides compounds (n-3 PUFA derivatives) of formula (I) that modulate conditions associated with cardiac damage, especially cardiac arrhythmias.  
WO/2010/080795A2
Provided is a complex of hydrogen peroxide and at least one compound represented by Formula (I): wherein X is ( ), -C(R3)3, -C=C(R3), -O(R3), -N(R3)2, or -S(R3); and R1, R2, and R3 are each independently selected from H, alkyl, alkenyl, ...  
WO/2010/075636A1
The present invention provides in part a compound of Formula (I) or a pharmaceutically- acceptable salt or stereoisomer thereof: where R1 is selected from the group consisting of a substituted triazole group, a guanidine group, a urea gr...  
WO/2010/046181A3
The invention relates to substances for defoaming aqueous media. Said substances contain urea derivatives of formula (I) in the form of solid particles as defoaming agents. In formula (I), R1 is a hydrocarbon group comprising 4 to 30 car...  
WO/2010/067005A1
The present invention relates to a method for preparing an allophanate, as well as to an allophanate and to a reduced viscosity polyisocyanate composition that contains the allophanate, intended for coating compositions, particularly pai...  
WO/2010/065902A2
A compound of Formula (I), a pharmaceutically acceptable salt, or solvate thereof, complexes with metals such as rhenium, technetium, and others to provide a complex for imaging tissues or treating disease, particularly where the metal i...  
WO/2010/063358A1
The invention relates to a method for producing a solution comprising urea urethanes and acting as a thixotropic agent, wherein at least two structurally different monohydroxy compounds are converted by an excess of toluylene diisocyanat...  
WO/2010/062158A2
The present invention relates to the synthesis of lipophilic or immobilized monobasic phosphate (H2PO4) ionophores (7, 8a, 8b and 11) to be used as ion recognition molecules for monobasic phosphate (H2PO4") in the cocktail preparation of...  
WO/2010/053128A1
Provided is a liquid crystal aligning agent capable of forming a liquid crystal alignment film the surface of which is rarely scratched or abraded when rubbed, and which exhibits excellent liquid crystal aligning properties and enables t...  
WO/2010/046181A2
The invention relates to substances for defoaming aqueous media. Said substances contain urea derivatives of formula (I) in the form of solid particles as defoaming agents. In formula (I), R1 is a hydrocarbon group comprising 4 to 30 car...  
WO/2010/035427A1
Disclosed is a urea compound represented by general formula (1). (In the formula, X1, X2 and X3 independently represent a hydrogen atom, an alkyl group or an aryl group. The aryl group may have one or more functional groups selected fro...  
WO/2009/146539A8
Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity are disclosed. Specifically, a series of compounds containing 4-(aminome...  
WO/2010/024298A1
Disclosed is a compound represented by formula (I) [wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the description] or a pharmaceutically acceptable salt or solvate thereof.  
WO/2010/017470A1
The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composi...  
WO/2010/017060A1
This invention relates to compounds of the Formula (I):or a pharmaceutically acceptable salt, solvate, ester or isomer thereof, which is useful for the treatment of diseases or conditions mediated by LpxC.  
WO/2010/009508A1
A compound of Formula (A) wherein Z is an aryl, substituted aryl, heteroaryl, or substituted heteroaryl, wherein the heteroaryl or substituted heteroaryl connected to a 2,4-dinito-6-(trifluoromethyl)phenyl ring via a carbon-carbon bond.  
WO/2008/083054A3
Novel β1 adrenoreceptor ligands that find use as imaging agents within nuclear medicine applications (e.g., PET imaging and SPECT imaging) are provided. Methods of imaging, including methods of imaging congestive heart failure, are also...  
WO/2009/145989A3
Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGD2 receptors. Also described here...  
WO/2010/006085A1
The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprisi...  
WO/2009/130422A3
The present invention relates to the use of acylthiourea or acylurea derivatives of formula (I) for the treatment of pathologies involving a tissue dysfunction associated with a deregulation of the Hedgehog protein signalling pathway, an...  
WO/2009/146539A1
Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity are disclosed. Specifically, a series of compounds containing 4-(aminome...  
WO/2009/145989A2
Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGD2 receptors. Also described here...  
WO/2009/069132A3
Compounds that are capable of inhibiting an activity of a reverse transcriptase are disclosed. Further disclosed are pharmaceutical compositions containing these compounds, and methods of inhibiting an activity of reverse transcriptase a...  
WO/2009/132978A1
This invention relates to novel 4-dimethylaminobutyric acid derivatives of the formula (I) wherein A1, A2, R1, m and n are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compo...  
WO/2009/130422A2
The present invention relates to the use of acylthiourea or acylurea derivatives of formula (I) for the treatment of pathologies involving a tissue dysfunction associated with a deregulation of the Hedgehog protein signalling pathway, an...  
WO/2009/130317A1
The present invention relates to novel heterocyclic compounds which are useful for inhibiting glycogen synthase kinase 3 (GSK-3), methods of making the compounds, compositions containing the compounds, and methods of treatment using the ...  
WO/2008/145615A3
The present invention relates to the use of aminoazoline and urea derivatives for com- bating animal pests. The invention also relates to a method for controlling animal pests by using these compounds, to seed and to an agricultural and ...  
WO/2009/121603A1
The invention relates to a method for producing at least one compound having at least one at least monosubstituted amino group. According to the invention, a starting substance supporting at least one amino group is reacted with an alcoh...  
WO/2009/121607A1
The invention relates to a method for producing a compound having at least one at least monosubstituted amino group. According to the invention, a starting substance supporting at least one amino group is reacted with a reagent supportin...  
WO/2009/124022A1
The invention provides amino- and amido-aminotetralin compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, and n are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opio...  
WO/2009/121843A1
Process for increasing the capacity of an existing urea plant comprising a high-pressure urea synthesis section and one or more recovery sections, wherein next to the existing urea plant a urea production unit, comprising a high-pressure...  
WO/2009/089541A3
A method for designing a molecule capable of functioning as a PEPCK inhibitor can include identifying a molecule that has a size capable of fitting into and interacting with the PEPCK binding site and at least one of the following: (a) a...  
WO/2009/115491A1
The present invention relates to azolin-2-ylamino compounds of formulae (I) and (II), wherein n is 0 to 3; Ar is phenyl; A is a radical of formulae A1 or A2, wherein * indicates the point of attachment; X is S, O or N(R10); R7a-d are H, ...  
WO/2009/053443A3
This invention provides new indane compounds, their use for the treatment or prevention of melatoninergic disorders and its compositions.  
WO/2009/117095A1
The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are...  
WO/2009/115040A1
Benzoylurea compounds having the structure of formula (I) and uses thereof, wherein: R1 and R2 are independently selected from H, F, Cl, Br and I; R3, R4, R5, R6 and R7 are independently selected from H, halogen, C1-C6alkyl, C1-C6alkoxyl...  
WO/2009/106351A1
The present invention provides a compound of formula (I): wherein: R1 is a group selected from -CH2OH1-NHCOH and R2 is a hydrogen atom; or R1 together with R2 form the group -NHC(O)CH=CH-, wherein the nitrogen atom is bound to the carbon...  

Matches 301 - 350 out of 6,220